Verzenio 200 mg

VERZENIO 200 MG tablets contain abemaciclib, a medication used in cancer treatment. This oral tablet is manufactured by Eli Lilly Canada Inc. and is designed to support specific therapeutic needs.

VERZENIO 200 MG tablets are commonly used in cancer treatment, particularly in combination with other therapies. Abemaciclib is a type of CDK4/6 inhibitor, which may help slow the progression of certain types of cancer. Patients should consult their healthcare provider to understand the specific uses of VERZENIO 200 MG tablets.

Common effects of VERZENIO 200 MG tablets may include fatigue, nausea, and diarrhea. Some individuals may experience appetite loss or hair thinning. It's important to note that effects can vary widely among users, and not everyone will experience the same symptoms.

VERZENIO 200 MG tablets should be handled with care and stored as directed. Patients should follow their healthcare provider's instructions regarding administration and monitor for any adverse reactions. It's crucial to inform your healthcare provider about any pre-existing conditions or other medications you are taking.

VERZENIO 200 MG tablets may interact with certain medications, including those metabolized by the liver's CYP3A enzyme system. Alcohol and other substances that affect liver function should be avoided unless approved by a healthcare provider. Always consult your healthcare provider before starting or stopping any medication.